The Development of a Micro Assay for Natural Killer and Lymphokine-Activated Killer Activity and Its Use in Monitoring the Purification of an Interleukin-2 Inhibitor
Abstract
The treatment of cancer is a constantly changing field and has recently expanded to include immunotherapy. One of the recent advances in cancer immunotherapy involves the infusion of lymphokine-activated killer (LAK) cells. The LAK cells are derived from the patient's own lymphocytes which are incubated with interleukin-2 (IL-2) for a few days. The IL-2 augments the cytotoxicity of a subpopulation of these lymphocytes, increasing their ability to kill tumor cells. As an adjunct to the LAK cells, interleukin-2 (IL-2) is often administered intravenously to maintain the LAK cells' enhanced cytotoxicity. Unfortunately, the high doses of IL-2 required for this LAK maintenance are often toxic to the patient. The purpose of this research was to partially purify the IL-2 inhibitor from normal mouse serum. The partially purified IL-2 inhibitor was used to induce antibody formation. The polyclonal antiserum was tested for its neutralizing capability and will be used to further purify and characterize the inhibitor. Keywords: Chemotherapy; Cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 1989
- Accession Number
- ADA218343
Entities
People
- Loraine H. Anderson
Organizations
- Air Force Institute of Technology